ERKKI RUOSLAHTI, M.D., Ph.D.
Founder, President, CEO
Dr. Ruoslahti is Distinguished Professor at Sanford Burnham Prebys Medical Discovery Institute and former President/CEO of the Institute. He has pioneered several important areas in biology, biochemistry and cancer research. He was one of the discoverers of fibronectin, discovered the RGD cell adhesion sequence in fibronectin and RGD-directed integrins. He subsequently developed in vivo phage display screening to identify tissue-specific targeting peptides, which resulted in the discovery of tumor-penetrating peptides, such as iRGD, and the CendR transport system in his laboratory. Dr. Ruoslahti is a member of the U.S. National Academy of Sciences, and National Academy of Medicine. His scientific awards include the Canadian Gairdner International Award and the Japan Prize. On the entrepreneurial side, Dr. Ruoslahti is an inventor of about 150 patents and a fellow of National Academy of Inventors. He has started a number of biotech companies as a founder, including DrugCendR. He is also currently, and has been in the past, a director of privately held companies and has served on the board of directors of two publicly traded companies, Telios Pharmaceuticals, and Advanced Cell Technologies.
For more information on Dr. Ruoslahti please visit: